XML 44 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2015:
 
 
Fair Value Measurements at
 
December 31, 2015
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
54,474,609

 
$
54,474,609

 
$

 
$

Mutual funds
78,385,992

 

 
78,385,992

 

US corporate debt securities
26,869,403

 

 
26,869,403

 

Municipal bonds
101,882

 

 
101,882

 

Investments in affiliated entities
19,987,192

 
19,987,192

 

 

Common stock warrants
5,970

 

 

 
5,970

Total Assets
$
179,825,048

 
$
74,461,801

 
$
105,357,277

 
$
5,970

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,301,138

 
$

 
$

 
$
1,301,138

Total Liabilities
$
1,301,138

 
$

 
$

 
$
1,301,138


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2014:
 
 
Fair Value Measurements at
 
December 31, 2014
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
36,474,066

 
$
36,474,066

 


 
$

Mutual funds
29,273,635

 

 
29,273,635

 

US corporate debt securities
23,802,339

 

 
23,802,339

 

Investment in affiliated entity
12,340,811

 
12,340,811

 

 

Common stock warrants
550,000

 

 

 
550,000

Total Assets
$
102,440,851

 
$
48,814,877

 
$
53,075,974

 
$
550,000

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
2,022,729

 
$

 
$

 
$
2,022,729

Total Liabilities
$
2,022,729

 
$

 
$

 
$
2,022,729

Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of common stock warrants at December 31, 2015 and 2014 are presented below:
 
 
Year Ended December 31,
 
2015
 
2014
Risk-free interest rate
1.36%
 
1.1%
Expected volatility
81%
 
81%
Expected life in years
2.70
 
3.70
Dividend yield
 
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the years ended December 31, 2015 and 2014:

 
Year Ended December 31,
 
2015
 
2014
Balance at beginning of year
$
550,000

 
$
717,500

Decrease in fair value included in change in fair value of common stock warrants
(544,030
)
 
(167,500
)
Balance at end of year
$
5,970

 
$
550,000



Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the years ended December 31, 2015 and 2014:
 
 
Year Ended December 31,
 
2015
 
2014
Balance at beginning of year
$
2,022,729

 
$
19,540,583

Decrease in fair value included in change in fair value of common stock warrants
(721,591
)
 
(515,643
)
Change in classification from liability to stockholders' equity due to warrant exercises

 
(17,002,211
)
Balance at end of year
$
1,301,138

 
$
2,022,729

OncoSec  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at December 31, 2015 and 2014 are presented below:

 
Year Ended December 31,
 
2015
 
2014
Risk-free interest rate
0.64%
 
0.67%
Expected volatility
90%
 
90%
Expected life in years
0.75-1.25
 
1.75-2.25
Dividend yield